Chris H. Takimoto

13.1k total citations · 3 hit papers
193 papers, 8.9k citations indexed

About

Chris H. Takimoto is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chris H. Takimoto has authored 193 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 76 papers in Molecular Biology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chris H. Takimoto's work include Cancer Treatment and Pharmacology (53 papers), Cancer therapeutics and mechanisms (38 papers) and Colorectal Cancer Treatments and Studies (37 papers). Chris H. Takimoto is often cited by papers focused on Cancer Treatment and Pharmacology (53 papers), Cancer therapeutics and mechanisms (38 papers) and Colorectal Cancer Treatments and Studies (37 papers). Chris H. Takimoto collaborates with scholars based in United States, United Kingdom and Spain. Chris H. Takimoto's co-authors include Anthony W. Tolcher, Eric K. Rowinsky, Manuel Hidalgo, Jean L. Grem, Lisa A. Hammond, Carmen J. Allegra, Susan G. Arbuck, Amita Patnaik, Ahmad Awada and Lillian L. Siu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Chris H. Takimoto

188 papers receiving 8.7k citations

Hit Papers

Expression of Epiregulin and Amphiregulin and K-ras Mutat... 2001 2026 2009 2017 2007 2001 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
    2007 898 citations Neal J. Meropol, Mark Basik et al. Journal of Clinical Oncology profile →
  2. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
    2001 830 citations Manuel Hidalgo, Lisa A. Hammond et al. Journal of Clinical Oncology profile →
  3. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    2012 336 citations Shobha Seetharam, Thomas A. Puchalski et al. Investigational New Drugs profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris H. Takimoto United States 45 4.8k 3.6k 2.5k 1.0k 1.0k 193 8.9k
Rajeshwari Sridhara United States 53 4.8k 1.0× 3.0k 0.8× 2.9k 1.1× 788 0.8× 644 0.6× 137 9.3k
Suzanne F. Jones United States 42 4.1k 0.9× 3.6k 1.0× 1.8k 0.7× 781 0.8× 561 0.6× 231 7.8k
Monica Mita United States 47 3.6k 0.7× 4.5k 1.3× 1.9k 0.7× 845 0.8× 686 0.7× 239 8.2k
Charles Erlichman United States 60 6.0k 1.2× 5.2k 1.5× 2.2k 0.9× 879 0.9× 1.8k 1.8× 313 12.0k
Wells A. Messersmith United States 52 5.3k 1.1× 4.3k 1.2× 1.8k 0.7× 1.1k 1.1× 1.2k 1.2× 298 9.5k
Gideon M. Blumenthal United States 47 4.0k 0.8× 2.4k 0.7× 2.6k 1.0× 926 0.9× 593 0.6× 119 7.5k
Siqing Fu United States 51 4.1k 0.9× 3.8k 1.1× 2.4k 1.0× 954 0.9× 1.2k 1.2× 412 9.6k
S. Percy Ivy United States 43 3.6k 0.8× 4.1k 1.2× 1.3k 0.5× 612 0.6× 752 0.7× 189 7.9k
Robert Justice United States 40 2.5k 0.5× 2.8k 0.8× 1.7k 0.7× 442 0.4× 558 0.6× 61 6.4k
Branimir I. Šikić United States 57 4.9k 1.0× 4.7k 1.3× 924 0.4× 681 0.7× 655 0.6× 225 9.6k

Countries citing papers authored by Chris H. Takimoto

Since Specialization
Citations

This map shows the geographic impact of Chris H. Takimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris H. Takimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris H. Takimoto more than expected).

Fields of papers citing papers by Chris H. Takimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris H. Takimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris H. Takimoto. The network helps show where Chris H. Takimoto may publish in the future.

Co-authorship network of co-authors of Chris H. Takimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Chris H. Takimoto. A scholar is included among the top collaborators of Chris H. Takimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris H. Takimoto. Chris H. Takimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takimoto, Chris H., Mark P. Chao, C. Parker Gibbs, et al.. (2019). The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target. Annals of Oncology. 30(3). 486–489. 90 indexed citations
2.
Feng, Dongdong, Phung Gip, Kelly M. McKenna, et al.. (2018). Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia. Blood. 132(Supplement 1). 2729–2729. 52 indexed citations
3.
Sankhala, Kamalesh K., Chris H. Takimoto, Alain C. Mita, et al.. (2018). Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Investigational New Drugs. 37(1). 76–86. 1 indexed citations
4.
Fetterly, Gerald J., Chris H. Takimoto, Shobha Seetharam, et al.. (2013). Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. The Journal of Clinical Pharmacology. 53(10). 1020–1027. 26 indexed citations
5.
Saif, Muhammad Wasif, Chris H. Takimoto, Monica Mita, et al.. (2013). A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(2). 445–455. 38 indexed citations
6.
Baselga, José, Alain C. Mita, Patrick Schöffski, et al.. (2012). Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research. 18(22). 6364–6372. 14 indexed citations
7.
Goel, Sanjay, Alain C. Mita, Monica Mita, et al.. (2009). A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 15(12). 4207–4212. 121 indexed citations
8.
Sweeney, Christopher J., Chris H. Takimoto, Leslie Wood, et al.. (2009). A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemotherapy and Pharmacology. 66(2). 345–356. 23 indexed citations
9.
Lakshman, Minalini, Li Xu, Vijayalakshmi Ananthanarayanan, et al.. (2008). Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice. Cancer Research. 68(6). 2024–2032. 135 indexed citations
10.
Sankhala, Kamalesh K., Chris H. Takimoto, Akira Mita, et al.. (2008). Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. Journal of Clinical Oncology. 26(15_suppl). 2577–2577. 3 indexed citations
11.
Phan, Alexandria T., Chris H. Takimoto, Leslie Wood, et al.. (2007). Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors.. Molecular Cancer Therapeutics. 6. 8 indexed citations
12.
Tolcher, Anthony W., Amita Patnaik, Kyriakos P. Papadopoulos, et al.. (2007). Safety and pharmacokinetics of oblimersen administered as a weekly 2-hour intravenous infusion. Molecular Cancer Therapeutics. 6. 1 indexed citations
13.
Garrett, Christopher, Edwin Clark, Mark Basik, et al.. (2007). Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab (Erbitux ®). Cancer Research. 67. 5670–5670. 3 indexed citations
14.
Sankhala, Kamalesh K., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations
15.
Tolcher, Anthony W., Desirée Hao, Johann S. de Bono, et al.. (2006). Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(13). 2052–2058. 34 indexed citations
16.
Ricart, Alejandro D., Anthony W. Tolcher, Quincy S. Chu, et al.. (2006). Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies. Cancer Research. 66. 685–685. 3 indexed citations
17.
Mita, Monica, Eric K. Rowinsky, Leonardo Forero, et al.. (2006). A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. 59(2). 165–174. 32 indexed citations
18.
Calvo, Emiliano, Andrew Goetz, Peter L. Bonate, et al.. (2005). Analysis of dose proportionality testing methods in phase I clinical trials of anticancer agents. Cancer Research. 65. 973–974. 1 indexed citations
19.
Egorin, Merrill J., Scot C. Remick, Daniel Mulkerin, et al.. (2004). Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. Journal of Clinical Oncology. 22(14_suppl). 6051–6051. 14 indexed citations
20.
Hao, Desirée, Lisa A. Hammond, Sabine Eckhardt, et al.. (2003). A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.. PubMed. 9(7). 2465–71. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajeshwari Sridhara Breakdown of academic impact, for papers by Suzanne F. Jones Breakdown of academic impact, for papers by Monica Mita Breakdown of academic impact, for papers by Charles Erlichman Breakdown of academic impact, for papers by Wells A. Messersmith Breakdown of academic impact, for papers by Gideon M. Blumenthal Breakdown of academic impact, for papers by Siqing Fu Breakdown of academic impact, for papers by S. Percy Ivy Breakdown of academic impact, for papers by Robert Justice Breakdown of academic impact, for papers by Branimir I. Šikić
Rankless by CCL
2026